Vogt-Koyanagi-Harada disease (VKHD): pathology
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Vogt-Koyanagi-Harada disease (VKHD): pathology. This is an autoimmune disease. The target are melanocyte antigens. Fully referenced neurology checklist.
Pathology
- This is an autoimmune disease
- The target are melanocyte antigens
- There is an HLA DR4 predisposition
Triggers
Locked: subscribe to see this section.
Risk populations
Locked: subscribe to see this section.
Demographic features
Locked: subscribe to see this section.
Clinical phases
Locked: subscribe to see this section.
References
- Lavezzo MM, Sakata VM, Morita C, et al. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis 2016; 11:29.
- Sood AB, O'Keefe G, Bui D, Jain N. Vogt-Koyanagi-Harada disease associated with hepatitis B vaccination. Ocul Immunol Inflamm 2019; 27:524-527.
- Yoshino N, Kawamura A, Ishii A, et al. Vogt-Koyanagi-Harada disease associated with influenza A virus infection. Intern Med 2018; 57:1661-1665.
- Dogan B, Erol MK, Cengiz A. Vogt-Koyanagi-Harada disease following BCG vaccination and tuberculosis. Springerplus 2016; 5:603.
- Tieger MG, Eliott D, Cakir B, Dahrouj M. Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada disease presenting 3 months following discontinuation of nivolumab. Ophthalmic Surg Lasers Imaging Retina 2023; 54:183-187.
- And 5 more. Subscribe to see the full list
